Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saar I Gill

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Best Practice & Research. Clinical Haematology|November 30, 2019
How close are we to CAR T-cell therapy for AML?Saar I Gill
JACC. Cardiooncology|January 13, 2023
Cancer Immunotherapy Beyond Checkpoint Blockade: <i>JACC: CardioOncology</i> State-of-the-Art ReviewNathan E Welty, Saar I Gill
Cell Stem Cell|February 9, 2019
21<sup>st</sup> Century FOX: Toward Gene Therapy for the Regulatory T Cell Deficiency Syndrome IPEXNicholas E Petty, Saar I Gill
Blood|April 7, 2022
Epigenetic engineering empowers T cellsJayesh V Tandel, Saar I Gill
Immunological Reviews|June 9, 2023
Good CARMA: Turning bad tumor-resident myeloid cells good with chimeric antigen receptor macrophagesChristopher M Snyder, Saar I Gill
Nature Communications|July 5, 2020
Cancer immunotherapy comes of age and looks for maturityAmanda Finck, Saar I Gill, Carl H June
Nature Reviews. Cancer|July 24, 2024
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistanceNils Wellhausen, Joanne Baek, Saar I Gill, et al.
Current Opinion in Immunology|November 19, 2021
Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapyNils Wellhausen, Sangya Agarwal, Philipp C Rommel, et al.
American Journal of Hematology|April 12, 2022
Salvage therapy with basiliximab and etanercept for severe steroid-refractory acute graft-versus-host diseaseCraig W Freyer, Shannon Gier, Alison Carulli, et al.
The American Journal of Cardiology|July 7, 2024
Symptomatic Heart Failure and Clonal Hematopoiesis-Related Mutations in Patients With Acute Myeloid LeukemiaYu Kang, Benedicte Lefebvre, Ingrid Marti Pamies, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Best Practice & Research. Clinical Haematology|November 30, 2019
How close are we to CAR T-cell therapy for AML?Saar I Gill
JACC. Cardiooncology|January 13, 2023
Cancer Immunotherapy Beyond Checkpoint Blockade: <i>JACC: CardioOncology</i> State-of-the-Art ReviewNathan E Welty, Saar I Gill
Cell Stem Cell|February 9, 2019
21<sup>st</sup> Century FOX: Toward Gene Therapy for the Regulatory T Cell Deficiency Syndrome IPEXNicholas E Petty, Saar I Gill
Blood|April 7, 2022
Epigenetic engineering empowers T cellsJayesh V Tandel, Saar I Gill
Immunological Reviews|June 9, 2023
Good CARMA: Turning bad tumor-resident myeloid cells good with chimeric antigen receptor macrophagesChristopher M Snyder, Saar I Gill
Nature Communications|July 5, 2020
Cancer immunotherapy comes of age and looks for maturityAmanda Finck, Saar I Gill, Carl H June
Nature Reviews. Cancer|July 24, 2024
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistanceNils Wellhausen, Joanne Baek, Saar I Gill, et al.
Current Opinion in Immunology|November 19, 2021
Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapyNils Wellhausen, Sangya Agarwal, Philipp C Rommel, et al.
American Journal of Hematology|April 12, 2022
Salvage therapy with basiliximab and etanercept for severe steroid-refractory acute graft-versus-host diseaseCraig W Freyer, Shannon Gier, Alison Carulli, et al.
The American Journal of Cardiology|July 7, 2024
Symptomatic Heart Failure and Clonal Hematopoiesis-Related Mutations in Patients With Acute Myeloid LeukemiaYu Kang, Benedicte Lefebvre, Ingrid Marti Pamies, et al.
Pageof 6